MEDCONN × HORIBA

Recently, Medconn entered into a strategic partnership with HORIBA Group and officially signed an agency agreement for its HbA1c analyzers with HORIBA's U.S. subsidiary.

The partnership marks an important milestone for Medconn's independently developed HbA1c analysis systems, which have now entered one of the world's most mature and highly regulated IVD markets. It represents another significant step forward for Chinese high-end medical technology on the global stage.

With more than 80 years of history, HORIBA Group is a globally recognized company with operations spanning clinical diagnostics, scientific analysis, automotive testing, and environmental monitoring. The Group has established a comprehensive global network covering R&D, manufacturing, and service capabilities.

As one of Medconn's core product lines, its HbA1c analyzers have previously obtained FDA clearance in the United States, providing a strong foundation for entering international markets in terms of product performance, quality systems, and regulatory compliance. The partnership with HORIBA's U.S. subsidiary not only marks an important milestone in Medconn's global expansion, but also reflects the recognition from its international partner of Medconn's technological innovation, product quality, and large-scale manufacturing capabilities.